← Back to Search

Aerobic Exercise for Breast Cancer Survivors (ROME Trial)

N/A
Recruiting
Led By Laura Q Rogers, MD, MPH
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 1-year post-completion of primary treatment for breast cancer (chemotherapy and/or radiation)
No antibiotics for the past 90 days
Must not have
Unstable angina
Anticipate elective surgery during the study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks after baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how exercise and a specific diet can change gut bacteria in breast cancer survivors to help reduce tiredness and improve health.

Who is the study for?
This trial is for women aged 18-74 who are breast cancer survivors (stage 0, I, II, or III) and have been free from primary treatment for at least a year. Participants should not be taking probiotics or antibiotics recently, must be able to walk without help, have low exercise capacity, experience fatigue, and get medical clearance.
What is being tested?
The study aims to explore how aerobic exercise affects the gut microbiome in breast cancer survivors and its potential link to reducing fatigue. Participants will either engage in an aerobic exercise program or be part of an attention control group that does not receive this intervention.
What are the potential side effects?
While specific side effects are not listed for this type of non-drug intervention, participants may experience general discomforts associated with new exercise routines such as muscle soreness or increased fatigue initially.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
It's been over a year since I finished my initial breast cancer treatment.
Select...
I haven't taken any antibiotics in the last 90 days.
Select...
I can walk on my own without help.
Select...
I have felt quite tired, rating my fatigue 3 or higher out of 10, over the last week.
Select...
I am a woman aged 18-74 with a history of early to mid-stage breast cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have unstable chest pain.
Select...
I am planning to have surgery during the study.
Select...
I expect to need antibiotics during the study.
Select...
I have not been diagnosed with any cancer other than skin or cervical cancer in situ in the past 5 years.
Select...
I have heart failure that affects my daily activities.
Select...
I live or work more than 50 miles away from the study site or I can't get there.
Select...
My BMI is over 50.
Select...
I am currently taking steroids.
Select...
My cancer has spread or come back.
Select...
My asthma is not well-managed.
Select...
I have interstitial lung disease.
Select...
I have a diagnosed connective tissue or rheumatologic disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks after baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks after baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composition of gut microbiota as measured by fecal samples
Secondary study objectives
Electrocardiogram
Concentration of cortisol measured through hair sample
Fatigue
+2 more
Other study objectives
Accelerometer Measured Free-living physical activity (e.g., minutes of activity)
Absorptiometry, X-Ray
FACT-B self-administered survey measuring quality of life
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Aerobic Exercise TrainingExperimental Treatment1 Intervention
Progressive aerobic exercise training sessions supervised by exercise specialists who have experience training cancer survivors.
Group II: Attention ControlActive Control1 Intervention
The non-aerobic exercise attention control condition will control for the effects of attention with flexibility/toning activities.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer include surgery, which physically removes the tumor; radiation therapy, which uses high-energy rays to kill cancer cells; chemotherapy, which uses drugs to destroy rapidly dividing cells; hormone therapy, which blocks hormones like estrogen that fuel certain cancers; and targeted therapy, which attacks specific molecules involved in cancer growth. Understanding these mechanisms is crucial for breast cancer patients as it informs the potential side effects and long-term impacts of treatment. For instance, exercise has been shown to positively affect the gut microbiome and reduce psychosocial symptoms such as fatigue, which can be particularly beneficial for patients dealing with the side effects of these treatments.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,017,934 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,646 Previous Clinical Trials
2,342,258 Total Patients Enrolled
Laura Q Rogers, MD, MPHPrincipal InvestigatorUniversity of Alabama at Birmingham
3 Previous Clinical Trials
96 Total Patients Enrolled

Media Library

Aerobic Exercise Training Clinical Trial Eligibility Overview. Trial Name: NCT04088708 — N/A
Fatigue and Malaise Research Study Groups: Aerobic Exercise Training, Attention Control
Fatigue and Malaise Clinical Trial 2023: Aerobic Exercise Training Highlights & Side Effects. Trial Name: NCT04088708 — N/A
Aerobic Exercise Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT04088708 — N/A
~17 spots leftby Aug 2025